Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen and Signalomics to Co-Develop Cancer Diagnostic Reagents

NEW YORK, April 11 (GenomeWeb News) - Invitrogen and Signalomics of Germany will collaborate to develop nanocrystal reagents for cancer diagnostics, Invitrogen said today.

 

Initially, the partners want to develop an imaging agent that can be used to identify colon carcinomas that require surgery.

 

Signalomics, based in Steinfurt, has been developing in vivo diagnostics based on designer proteins coupled to fluorescent semiconductor crystals. The proteins target faulty signaling proteins that are expressed in tumor tissues. In the body, they can be visualized by a laser light that makes the crystal-protein conjugates emit light in different colors.

 

The agreement allows Signalomics to continue its collaboration with BioPixels, which Invitrogen acquired in October. Signalomics has been working with BioPixels, a former business unit of BioCrystal, since 2004.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.